Craft

Myriad Genetics

Stock Price

$24.5

2024-06-28

Market Capitalization

$2.2 B

2024-06-28

Revenue

$753.2 M

FY, 2023

Myriad Genetics Summary

Company Summary

Overview
Myriad Genetics is a company that develops and offers genetic tests. It offers clinical trial testing, diagnostic development, cancer management, risk assessment, and other services. The company specializes in the areas of oncology, urology, imaging, mental health, primary care, etc.
Type
Public
Status
Active
Founded
1991
HQ
Salt Lake City, UT, US | view all locations
Website
https://www.myriad.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Paul J. Diaz

    Paul J. Diaz, President, CEO & Director

  • Bryan Riggsbee

    Bryan Riggsbee, Chief Financial Officer

  • Kevin R. Haas

    Kevin R. Haas, Chief Technology Officer

  • Jayne Hart

    Jayne Hart, EVP, Human Resources

Operating MetricsView all

Facilities Leased, sq. ft.

500.1K
33.6%

FY, 2022

Products

10

FY, 2021

Website Visitors

135K

FY, 2021

LocationsView all

6 locations detected

  • Salt Lake City, UT HQ

    United States

    322 North 2200 West

  • Paris, IDF

    France

    41 Rue Camille Desmoulins

  • Munich, BY

    Germany

    Staffelseestraße 6

  • Tokyo, Tokyo

    Japan

    Shinjuku Mitsui Building 55F 2-1-1 Nishishinjuku

  • Amsterdam, NH

    Netherlands

    Schiphol Boulevard 231

  • Zürich, ZH

    Switzerland

    Leutschenbachstrasse 95

Myriad Genetics Financials

Summary Financials

Revenue (Q1, 2024)
$202.2M
Gross profit (Q1, 2024)
$137.6M
Net income (Q1, 2024)
($26.0M)
Cash (Q1, 2024)
$96.9M
EBIT (Q1, 2024)
($27.9M)
Enterprise value
$2.3B

Footer menu